Navigation Links
Gentag, Inc. and MacroArray Technologies Join Forces
Date:6/9/2008

WASHINGTON, June 9 /PRNewswire/ -- Gentag, Inc. and MacroArray Technologies, LLC have entered into a development program to design a wireless immunoassay incorporating Gentag's cell phone communication technology and MacroArray's urine diagnostic test for prostate cancer.

One in six males are at risk of developing prostate cancer, but unfortunately not all men are being tested. In order to simplify and expand the use of low cost wireless diagnostic assays for early cancer detection, Gentag, Inc. and MacroArray Technologies have teamed to develop a new wireless test platform that will incorporate Gentag's cell phone-sensor technology with MacroArray's proteomics discovery technology to create a series of new, patient friendly, disposable, wireless diagnostic tests. The first of these will be a test for prostate cancer based on MacroArray's proprietary reagents.

Similar to the currently available pregnancy strip test, men will place a urine sample on the test strip that incorporates an imbedded wireless sensor tag. The antibodies in the strip test will react with the antigens in the urine, the resulting data will be sensed by the imbedded electronic tag and communicated to a cell phone or PDA that will process the data and transmit the results to the attending physician.

During the past year, approximately 60 million PSA tests were performed worldwide and over 200,000 men were diagnosed with prostate cancer. Nearly 35,000 will die each year from the disease. It is hoped that the availability of a simple low cost urine-based test will increase the number of men who evaluate their prostate health on a regular basis.

"The proprietary technology from Gentag combined with MacroArray's biomarkers will provide a significant level of exclusivity in this market," commented Dr. John Peeters, CEO of Gentag. "The combination of our two companies will dramatically expand the utility of our diagnostic tests," commented Mr. Mike Wassil, CEO of MacroArray.

About MacroArray Technologies

MacroArray Technologies is a theranostics company with a proprietary proteomics discovery platform that provides the rapid ability to identify novel biomarkers for diseases such as cancer. Their goal is to provide products for early detection leading to better medical and economic outcomes. The company has a number of tests in development including the Pre-Malignant Prostate cancer and an early stage biomarker for colon cancer.

About Gentag, Inc.

Gentag, Inc. is a technology development company focusing on innovative, low-cost, wireless sensor network technologies based on cell phones. The company owns unique intellectual property relating to cell phone-sensor combinations and wireless sensor networks, including patents 7,109,859 and 7,148,803. The effective combination of cell phone reader technology with a disposable sensor platform has led to a variety of medical diagnostic applications providing consumers, physicians, and various industries with instant access to vital information over established wireless networks, the Internet, and client-specific databases. The company is the recipient of the 2008 North American Technology Innovation Award from Frost & Sullivan.

For inquiries, please contact Marc Onigman at (617)-413-2830. For licensing or investment opportunities please contact Mr. Tom Stagnaro at tom.stagnaro@gentag.com.

For more information, visit:

http://www.gentag.com/

http://www.macroarraytechnologies.com/


'/>"/>
SOURCE Gentag, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
2. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
3. VNUS Medical Technologies Announces Resignation of Chief Financial Officer and VP, Finance & Administration
4. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
5. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
6. Advanced technologies aim to transform the coaching of top athletes
7. Global Med Technologies(R) Extends Its Worldwide Outreach
8. Acuo Technologies(R) Names Mike Dolan Vice President of Sales
9. ReBuilder Medical Technologies, Inc. Signs Agreement for Distribution in Maine
10. Neurobiological Technologies Reports Going Concern Qualification
11. MedCom USAs Subsidiary Card Activation Technologies, Inc.s SB2 Registration Declared Effective by SEC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , ... February 12, 2016 , ... ... Cancer Care.” , The print component of “Revolutionizing Cancer Care” is ... New York, Washington DC/Baltimore, and Seattle, with a circulation of approximately 250,000 copies ...
(Date:2/12/2016)... ... February 12, 2016 , ... US Sport Camps is pleased to announce ... located in Norwalk, serves as the host site and directing the camps is PGA ... have had successful camps in recent years around Des Moines and are fortunate to ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... explosive growth in the field of long term care. With that, says Patrick ... well-trained healthcare professionals in administrative roles in long term care environments. His company, ...
(Date:2/12/2016)... ... ... of restorative dentistry, to date there has been no other option in the U.S. to ... is a now a new protocol in stopping cavity progression; Silver Diamine Fluoride (SDF). ... The application is as simple as drying the tooth and applying the SDF to ...
(Date:2/11/2016)... CA (PRWEB) , ... February 11, 2016 , ... According ... System, a product marketed as a weight loss dietary supplement, is being recalled due ... group Beverly Hills Physicians, because there is not a single supplement on the market ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 12. Februar 2016  Sequent Medical, Inc. gab ... Patienten für eine Studie zur Sicherheit und Wirksamkeit ... für die Behandlung von rupturierten intrakraniellen Aneurysmen begonnen ... der Neuroradiologie an der Universitätsklinik Bicètre in ... CLARYS-Studie hat den ersten Patienten aufgenommen. ...
(Date:2/12/2016)... SEOUL, South Korea , Feb. 12, ... Inc. today announced they will form a partnership ... precision medicine in cancer. The goal of the ... technology with Macrogen,s high-throughput Next Generation Sequencing capabilities ... Clinical Laboratory Improvement Amendments (CLIA) of 1988 by ...
(Date:2/12/2016)... 12 februari 2016 AAIPharma Services ... leverancier van productie en ontwikkeling op maat ... vandaag een uitbreiding aan van steriele vul- ... in Charleston, SC . ... meerdere recente investeringen. http://photos.prnewswire.com/prnh/20150806/256637LOGO ...
Breaking Medicine Technology: